Chemotherapy‐induced prospective memory impairment in patients with breast cancer

Huang, Cheng; Yang, Zhen; Dong, Biao; Chen, Chanjuan; Zhang, Mingjun; Huang, Zhonglian; Chen, Zhendong; Wang, Kai

doi:10.1002/pon.3291

Cited by 45 publications

(44 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our finding is in line with most previous studies in that cognitive impairment in chemobrain affects mainly executive functions and presents as a memory deficit192021. However, most studies tested retrospective memory, while the performance of prospective memory was rarely reported67. Paquet and colleagues were the first to report that prospective memory was impaired in breast cancer survivors using Memory for Intention Screening Test, and found that fatigue might modulate this deficit7.…”

Section: Discussionsupporting

confidence: 91%

“…Paquet and colleagues were the first to report that prospective memory was impaired in breast cancer survivors using Memory for Intention Screening Test, and found that fatigue might modulate this deficit7. Our previous study also demonstrated that the EBPM was mainly affected while TBPM was relatively preserved in patients with breast cancer 6.In the present study, the performance in both EBPM and TBPM was found to be impaired in CC patients. The differences in the results between these two studies might arise from different patient traits, as the average age was higher while the educational score was lower in our present study.…”

Section: Discussionsupporting

confidence: 64%

“…Results of a recent meta-analysis suggest that long-term cognitive deficits after chemotherapy in patients with breast cancer are, for the most part, small in magnitude5. Our previous study identified a subpopulation of patients with breast cancer who after chemotherapy show prospective memory (PM) impairment6. Moreover, it has been indicated that breast cancer survivors exhibit a clear pattern of PM, and that fatigue is a major contributor to this deficit7.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Altered resting-state hippocampal functional networks associated with chemotherapy-induced prospective memory impairment in breast cancer survivors

Huang

Gong

et al. 2017

Sci Rep

Self Cite

View full text Add to dashboard Cite

In this study, we aimed to investigate the intrinsic hippocampal functional connectivity (FC) network and its relationship with prospective memory in patients with breast cancer suffering from chemotherapy-induced cognitive impairment (CICI). Thirty-four breast cancer patients before and after adjuvant chemotherapy (CB and CC, respectively) and 31 age- and education-matched cognitively normal (CN) women were recruited and subjected to a prospective memory task and a resting-state functional magnetic resonance imaging scan. Seed-based functional connectivity analysis was used to compare the hippocampal FC networks between CC and CN groups. Partial correction analysis was used to examine the association between the hippocampal FC network and prospective memory in the CC group. The cancer group that underwent chemotherapy obtained significantly poorer scores than the CN group on mini-mental state examination, verbal fluency test, digit span, and prospective memory examination. Compared to the CN group, CC group showed increased hippocampal connectivity in the frontal and parietal cortex, precuneus, posterior cingulate cortex, and the cerebellum. In addition, the increasing hippocampal FC networks were negatively correlated with prospective memory performance in the CC group. These findings suggest maladaptive hippocampal functioning as a mechanism underlying the impairment of prospective memory in patients experiencing CICI.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 64%

mentioning

confidence: 99%

See 1 more Smart Citation

Altered resting-state hippocampal functional networks associated with chemotherapy-induced prospective memory impairment in breast cancer survivors

Huang

Gong

et al. 2017

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…[7] PM is typically assessed with a dual-task paradigm (a PM task and an ongoing task), [8] and as our previous study demonstrated, patients with breast cancer who had undergone adjuvant chemotherapy showed deficits in EBPM tasks, but not in TBPM tasks. [9] …”

Section: Introductionmentioning

confidence: 99%

Chemotherapy-induced prospective memory impairment in breast cancer patients with different hormone receptor expression

Gan²,

Y³

et al. 2017

Medicine

Self Cite

View full text Add to dashboard Cite

This study aimed to investigate prospective memory impairment in patients with breast cancer with different expression of hormone receptors, including the estrogen receptor (ER) and the progesterone receptor (PR).A total of 120 patients with breast cancer who underwent chemotherapy following surgery were divided into 2 groups. The A group included 60 patients with ER−/PR− status, and the B group included 60 patients with ER+/PR+ status. After 6 cycles of postoperative adjuvant chemotherapy, all patients were administered neuropsychological and prospective memory tests, such as the Mini-Mental State Examination (MMSE), verbal fluency test (VFT), and digit span test (DST), as well as examination of event-based prospective memory (EBPM) and time-based prospective memory (TBPM).As the neuropsychological background test results showed, there were no significant differences in MMSE, DST, and TBPM scores (∗:P > 0.05) between patients with breast cancer in the ER−/PR− and ER+/PR+ groups, while the VFT and EBPM scores were significantly greater in patients with breast cancer with ER+/PR+ status than in those with ER−/PR− status (∗∗: P < 0.01), indicating that patients with ER−/PR− status have significant impairment in EBPM, although not in TBPM.The results of the present study indicate that different hormone receptor expression in patients with breast cancer may be associated with heterogeneity of chemotherapy-induced prospective memory impairment.

show abstract

“…CICI is well-documented in women receiving chemotherapy for breast cancer (van Dam et al, 1998; Villanueva, 2012; Jim et al, 2012, Reuter-Lorenz and Cimprich, 2013) and has been recapitulated in numerous mouse and rat models (Gandal et al, 2008; Seigers and Fardell, 2011; Winocur et al, 2012). Because the median survival for breast cancer patients has improved significantly in recent decades, the patients' quality of life following chemotherapy must be carefully considered as part of survivor care (Raffa, 2011, Cheng et al, 2013). Our particular focus is on patients with triple-negative breast cancer (TNBC), in which tumors cells do not express estrogen receptor-alpha, progesterone receptor, or human epidermal growth factor receptor 2/neu (Foulkes et al, 2010; Holliday and Speirs, 2011).…”

Section: Introductionmentioning

confidence: 99%

Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer

Himmel

Lustberg

DeVries

et al. 2016

Experimental and Toxicologic Pathology

View full text Add to dashboard Cite

Minocycline is purported to have neuroprotective properties in experimental models of some human neurologic diseases, and has therefore been identified as a putative neuroprotectant for chemotherapy-induced cognitive impairment (CICI) in breast cancer patients. However, because its mechanism of action is believed to be mediated through anti-inflammatory, anti-apoptotic, and anti-oxidant pathways, co-administration of minocycline with chemotherapeutic agents has the potential to reduce the efficacy of anticancer drugs. The objective of this study is to evaluate the effect of minocycline on the activity of the AC chemotherapeutic regimen (Adriamycin [doxorubicin], Cytoxan [cyclophosphamide]) in in vitro and in vivo models of triple-negative breast cancer (TNBC). Clonogenic and methylthiazol tetrazolium (MTT) assays were used to assess survival and viability in two TNBC cell lines treated with increasing concentrations of AC in the presence or absence of minocycline. Biomarkers of apoptosis, cell stress, and DNA damage were evaluated by western blot. The in vivo effects of AC and minocycline, each alone and in combination, were assessed in a xenograft model of TNBC in female athymic nude mice by weekly tumor volume measurement, body and organ weight measurement, and histopathology. Apoptosis and proliferation were characterized by immunohistochemistry in the xenografts tumors. Brains from tumor-bearing mice were evaluated for microglial activation, glial scars, and the proportion of neural progenitor cells. Data from these in vitro and in vivo studies demonstrate that minocycline does not diminish the cytotoxic and tumor-suppressive effects of this chemotherapeutic drug combination in TNBC cells. Moreover, minocycline appeared to prevent the reduction in doublecortin-positive neural progenitor cells observed in AC-treated mice. We posit that minocycline may be useful clinically for its reported neuroprotective activity in breast cancer patients receiving AC without loss of chemotherapeutic efficacy.

show abstract

Chemotherapy‐induced prospective memory impairment in patients with breast cancer

Abstract: Our results suggest that breast cancer patients who had undergone adjuvant chemotherapy show deficits in EBPM but not in TBPM.

Cited by 45 publications

References 40 publications

Altered resting-state hippocampal functional networks associated with chemotherapy-induced prospective memory impairment in breast cancer survivors

Altered resting-state hippocampal functional networks associated with chemotherapy-induced prospective memory impairment in breast cancer survivors

Chemotherapy-induced prospective memory impairment in breast cancer patients with different hormone receptor expression

Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer

Contact Info

Product

Resources

About